Table 2.
Primary and secondary outcomes of atorvastatin initiators and rosuvastatin initiators.
| Outcome measures | Atorvastatin (n = 2605) | Rosuvastatin (n = 717) |
|---|---|---|
| Primary outcomes | ||
| mRS score of 0 at 3 months | ||
| No of events | 1080 | 320 |
| Event rate (%) | 41.46% | 44.63% |
| Absolute rate difference | Reference | 3.17 |
| Relative rate (95% CI) | Reference | 1.12 (1.03, 1.22) |
| P value | Reference | 0.0076 |
| E value (95% LCI) | Reference | 1.49 (1.21) |
| Secondary outcomes | ||
| mRS score of 0 at discharge | ||
| No of events | 856 | 276 |
| Event rate (%) | 32.86% | 38.49% |
| Absolute rate difference | Reference | 5.63 |
| Relative rate (95% CI) | Reference | 1.20 (1.08, 1.32) |
| P value | Reference | 0.0003 |
| E value (95% LCI) | Reference | 1.69 (1.37) |
| mRS score of 0 at 6 months | ||
| No of events | 1171 | 357 |
| Event rate (%) | 44.95% | 49.79% |
| Absolute rate difference | Reference | 4.84 |
| Relative rate (95% CI) | Reference | 1.10 (1.01, 1.19) |
| P value | Reference | 0.016 |
| E value (95% LCI) | Reference | 1.43 (1.11) |
| mRS score of 0 at 12 months | ||
| No of events | 1242 | 362 |
| Event rate (%) | 47.68% | 50.49% |
| Absolute rate difference | Reference | 2.81 |
| Relative rate (95% CI) | Reference | 1.07 (0.99, 1.15) |
| P value | Reference | 0.084 |
| E value (95% LCI) | Reference | 1.34 (1.00) |
| Stroke recurrence in 12 months | ||
| No of events | 112 | 34 |
| Event rate (%) | 4.30% | 4.74% |
| Median (P25, P75) follow-up days | 367 (363, 375) | 368 (361, 380) |
| Absolute rate difference | Reference | 0.44 |
| Hazard ratio (95% CI) | Reference | 1.08 (0.74, 1.59) |
| P value | Reference | 0.68 |
| E value (95% LCI) | Reference | 1.37 (1.00) |
| All-cause mortality in 12 months | ||
| No of events | 91 | 27 |
| Event rate (%) | 3.49% | 3.77% |
| Median (P25, P75) follow-up days | 368 (364, 376) | 369 (364, 382) |
| Absolute rate difference | Reference | 0.28 |
| Hazard ratio (95% CI) | Reference | 1.07 (0.70, 1.65) |
| P value | Reference | 0.76 |
| E value (95% LCI) | Reference | 1.34 (1.00) |
| Cardiovascular mortality in 12 months | ||
| No of events | 68 | 20 |
| Event rate (%) | 2.61% | 2.79% |
| Median (P25, P75) follow-up days | 368 (364, 376) | 369 (364, 382) |
| Absolute rate difference | Reference | 0.18 |
| Hazard ratio (95% CI) | Reference | 1.04 (0.63, 1.73) |
| P value | Reference | 0.87 |
| E value (95% LCI) | Reference | 1.24 (1.00) |
| MACE in 12 months | ||
| No of events | 188 | 55 |
| Event rate (%) | 7.22% | 7.67% |
| Median (P25, P75) follow-up days | 367 (363, 375) | 368 (361, 380) |
| Absolute rate difference | Reference | 0.45 |
| Hazard ratio (95% CI) | Reference | 1.04 (0.77, 1.41) |
| P value | Reference | 0.79 |
| E value (95% LCI) | Reference | 1.24 (1.00) |
CI, confidence interval; LCI, lower confidence interval; MACE, major adverse cardiovascular events; mRS, modified Rankin Scale; NNT, number needed to treat; P25, 25th percentile; P75, 75th percentile.